Medicare Trends in Intravitreal Anti-VEGF Use
Open Access
- 10 March 2026
- journal article
- Published by Elsevier in Ophthalmology Retina
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical TrialsOphthalmology and Therapy, 2025
- Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® RegistryOphthalmology and Therapy, 2024
- Medicare Part B Spending on Macular Degeneration Treatments Associated With Manufacturer Payments to OphthalmologistsJAMA Health Forum, 2023
- Faricimab: First ApprovalDrugs, 2022
- Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2021
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2020
- Analysis of Anti–Vascular Endothelial Growth Factor Injection Claims Data in US Medicare Part B Beneficiaries From 2012 to 2015JAMA Ophthalmology, 2019
- Physician-Industry Interactions and Anti–Vascular Endothelial Growth Factor Use Among US OphthalmologistsJAMA Ophthalmology, 2016
- Prevalence of and Risk Factors for Diabetic Macular Edema in the United StatesJAMA Ophthalmology, 2014
- Racial Differences in the Prevalence of Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2008